EKSO

Ekso Bionics carries a Neutral rating, supported by a composite score in the high 30s and moderate conviction. Regulatory is the strongest pillar at 49, followed by market at 40, fundamentals at 31, and editorial at 30. The regulatory contribution reflects an enforcement subscore of 80 and a jurisdiction score of 50, partly offset by a cadence score of 25. Market support remains constrained because no institutional pricing quote is available. Fundamentals provide limited backing despite strong gross-margin economics, while the editorial pillar reflects no recent newsroom or brief activity. The resulting profile lacks enough breadth for Overweight but retains sufficient regulatory support to avoid Underweight.

Licensed fundamentals data show year-over-year revenue contraction of approximately 38%, sharply limiting the growth contribution. Gross margin remains the principal operating strength at roughly 53%, consistent with the elevated gross-margin subscore. That advantage is overwhelmed by an operating margin near negative 120%, EBITDA loss of about $11.0 million, and net loss approaching $11.7 million. The cash-burn ratio stands near 26%, while the cash-runway subscore of 41 indicates continued funding pressure under the stated stretched financial condition. Market capitalization is approximately $42 million, aligning with a modest size-tier contribution. Primary regulatory filings show no dated latest filing, while no regulatory events appeared across either the recent 90-day or 180-day windows. CIN newsroom coverage also recorded no newsroom hits or brief hits, explaining the weak editorial contribution.

The clearest upside catalyst is renewed primary regulatory filing activity, because regulatory already leads the pillar set and benefits from a strong enforcement record. A current filing could lift the depressed cadence component, improve visibility into commercial execution, and provide updated evidence on whether gross-margin strength can translate into narrower operating and EBITDA losses. That catalyst carries greater rating relevance than market or editorial developments because the market pillar lacks an institutional quote and CIN newsroom coverage contains no active signal. The single most important signal to watch is a new primary regulatory filing that restores cadence and documents measurable progress toward lower operating losses.